EOSINOPENIA: an early, effective and relevant COVID-19 biomarker?
2020; Oxford University Press; Volume: 114; Issue: 1 Linguagem: Inglês
10.1093/qjmed/hcaa259
ISSN1460-2725
AutoresElena Roca, Laura Ventura, Costanza Maria Zattra, Carlo Lombardi,
Tópico(s)COVID-19 Clinical Research Studies
ResumoWe have read with interest the article of Lippi et al. 'Eosinophil count in severe coronavirus disease 2019 (COVID-19)'. 1 The authors argue that there is an association between eosinophil count and COVID-19, but that eosinopenia appears not to be associated with the unfavourable progression of the disease.Actually, there are not a lot of studies about this topic and those that exist relate to the Chinese case series.We report our case history relating to patients admitted to our COVID-19 Unit in our hospital in Brescia, one of the Northern Italian cities most affected by the SARS-Cov-2.Eosinophils originate from CD34þstem cells in the bone marrow as terminally differentiated cells; in fact, they no longer proliferate once formed. 2,3Under physiological conditions, the eosinophil count only covers a small percentage of circulating leukocytes, about 1-3%, but their levels may vary in different conditions. 4n the MERS-CoV, like in COVID-19, was demonstrated that patients had extensive inflammatory cellular infiltrates in the interstitium and alveoli 5 and, furthermore, they contribute to lung damage as they compromise lung function too. 2 Consequently, some authors speculated that probably neutrophils, eosinophilis, macrophages and lymphocytes migrate from peripheral blood into the lung tissue, causing neutropenia, eosinopenia lymphopenia. 6lso in Italian patients admitted to our Unit, it was shown a significant decrease in circulating eosinophils.In the 294 patients (M/F ¼ 88/206; age range: 24-95 years; mean age: 68.8 years) admitted to our Unit, the median value of eosinophil count was 0.01 Â 10 9 /l (mean 0.028, SD 6 0.04).Moreover, it was shown that in 246 patients (83.7%) there was a decrease in
Referência(s)